Frontier Scientific develops and provides process to produce active pharmaceutical ingredient for clinical trial of Covid-19 therapeutic investigational drug RBT-9

This article was originally published here

Frontier Scientific identified and developed multiple synthetic processes to produce stannous protoporphyrin (SnPP) – the active pharmaceutical ingredient of RBT-9, an investigational drug entering a Phase 2 trial

The post Frontier Scientific develops and provides process to produce active pharmaceutical ingredient for clinical trial of Covid-19 therapeutic investigational drug RBT-9 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply